Specific Parameters of Toxic Reactions in Rats to the Combination of Delamanid and Drugs for Treatment of Drug Resistant Tuberculosis (A Pilot Study)

Specific Parameters of Toxic Reactions in Rats to the Combination of Delamanid and Drugs for Treatment of Drug Resistant Tuberculosis (A Pilot Study)

The objective: to evaluate the toxicity of combinations of delamanid and drugs for treatment of drug resistant tuberculosis with different safety profiles in an experiment.Results. During 14 days of the study, the animals of both experimental groups satisfactorily tolerated the administration of dru...

Full description

Saved in:

Bibliographic Details
Main Authors:	G. N. Mozhokina, L. Yu. Petrova, A. G. Samoylova, A. V. Abramchenko
Format:	Article
Language:	Russian
Published:	New Terra Publishing House 2023-04-01
Series:	Туберкулез и болезни лёгких
Subjects:	anti-tuberculosis drugs delamanid adverse events experiment
Online Access:	https://www.tibl-journal.com/jour/article/view/1717
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Delamanid: Safety and Efficacy Analysis
by: G. N. Mozhokina, et al.
Published: (2023-12-01)

New drugs in the treatment of drug-resistant tuberculosis in children. Experience with the use of delamanid in combination with bedaquiline
by: Ekaterina Sokolskaya, et al.
Published: (2024-12-01)

Experience of Using Delamanid in the Treatment of Multiple Drug Resistant Tuberculosis
by: T. R. Bagdasaryan, et al.
Published: (2024-10-01)

Delamanid is a new anti-tuberculosis drug: use, limitations, and prospects
by: V. N. Zimina, et al.
Published: (2021-03-01)

Perspectives of targeted chemotherapy with delamanid in the treatment regimens of those with multiple/extensive drug resistant tuberculosis. A success, chance or uncertainty?
by: Aleksey G. Naumov, et al.
Published: (2018-11-01)

Nephrotoxic characteristics of anti-tuberculosis drugs
by: G. N. Mozhokina, et al.
Published: (2019-11-01)

Investigation of delamanid, bedaquiline, and linezolid resistance rates and related gene mutations in multidrug-resistant Mycobacterium tuberculosis in regional tuberculosis reference laboratories of Iran
by: Nazanin Ahmad Khosravi, et al.
Published: (2025-08-01)

Drug resistance of Mycobacterium tuberculosis to linezolid and delamanid: a case report from Bukavu, Democratic Republic of Congo
by: Bertin C. Bisimwa, et al.
Published: (2025-07-01)

The problem of neurotoxicity of drugs in the treatment of tuberculosis patients
by: G. N. Mozhokina, et al.
Published: (2020-11-01)

Distribution of Minimum Inhibitory Concentrations and Resistance-associated Gene Mutations in Multidrug-resistant Mycobacterium tuberculosis Strains from Southern Türkiye: Insights on Bedaquiline, Delamanid, and Linezolid
by: Huda Ahmed, et al.
Published: (2024-12-01)

Variety of Adverse Reactions in Rats after Administration of Combination of Anti-tuberculosis and Antimicrobial Drugs with Different Safety Profiles
by: G. N. Mozhokina, et al.
Published: (2022-11-01)

The Use of Nootropic Drugs to Reduce Toxic Reactions in Rats to a Combination of Anti-Tuberculosis Drugs
by: G. N. Mozhokina, et al.
Published: (2024-12-01)

Use of Short Oral Regimens for Treatment of Drug Resistant Tuberculosis in a Patient with HIV Infection
by: S. Yu. Degtyareva, et al.
Published: (2023-03-01)

Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives
by: A. E. Russkikh, et al.
Published: (2021-01-01)

Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
by: E. S. Khimova, et al.
Published: (2023-07-01)

Specific Manifestations of Neurotoxicity of Some Drug Combinations for Treatment of Drug Resistant Tuberculosis from the Perspective of Experimental Studies
by: G. N. Mozhokina, et al.
Published: (2023-01-01)

Possibilities of Using Nootropic Drugs to Reduce Neurotoxic Reactions Caused by Anti-tuberculosis Drugs in Experimental Conditions
by: G. N. Mozhokina, et al.
Published: (2024-07-01)

Frequency and characteristics of adverse events caused by anti-tuberculosis drugs in pulmonary tuberculosis patients with diabetes myelitis
by: O. G. Komissarova, et al.
Published: (2020-03-01)

Safety and Efficacy of Multiple Drug Resistant Tuberculosis Treatment in Patients with Different HIV Statuses
by: S. Yu. Degtyareva, et al.
Published: (2022-02-01)

TO DISCONTINUE OR TO WAIT?: INDICATIONS FOR DISCONTINUATION OF ANTI-TUBERCULOSIS DRUGS DUE TO ADVERSE EVENTS
by: D. A. Ivаnovа, et al.
Published: (2018-03-01)

Clofazimine: History and Perspectives
by: G. N. Mozhokina, et al.
Published: (2021-06-01)

Occurrence and predictors of adverse events associated with linezolid in the treatment of patients with drug resistant tuberculosis and their impact on treatment outcomes
by: Abhirami V, et al.
Published: (2025-06-01)

Toxicity of treatment regimens for drugresistant tuberculosis.
by: G. N. Mozhokina, et al.
Published: (2022-03-01)

Treatment outcomes in cavitary multidrug-resistant/rifampicin-resistant tuberculosis and risk factors for cavity closure: a retrospective cohort study in Southwest China
by: Qing Chen, et al.
Published: (2025-07-01)

Parameters of hepatotoxic reactions caused by the combination of first line anti-tuberculosis drugs in rats with different acetylation phenotypes
by: G. N. Mozhokina, et al.
Published: (2020-08-01)

Adverse drug reactions of first-line antitubercular drugs: A retrospective study on characteristics, management, factors, and impacts
by: Ai Ling Oh, et al.
Published: (2024-10-01)

Prevalence, clinical reasons and associated factors of extended treatment duration for drug susceptible tuberculosis – a real-world experience
by: Chih-Yu Liu, et al.
Published: (2025-04-01)

Clinical Efficacy and Safety of Clofazimine in Treatment Regimens for Drug Resistant Tuberculosis (Meta-Analysis)
by: A. I. Gayda, et al.
Published: (2024-05-01)

Medications for Short-Course Chemotherapy of Drug Resistant Tuberculosis and Their Effect on the Host
by: G. N. Mozhokina, et al.
Published: (2022-09-01)

FREQUENCY AND CHARACTERISTICS OF ADVERSE REACTIONS TO SECOND LINE ANTI-TUBERCULOSIS DRUGS IN THOSE ILL WITH MULTIPLE DRUG RESISTANT TUBERCULOSIS
by: A. A. Toktogonova
Published: (2017-11-01)

THE SAFETY OF TREATMENT OF MULTIPLE DRUG RESISTANT TUBERCULOSIS IN HIV POSITIVE PATIENTS RECEIVING ANTIRETROVIRAL THERAPY
by: S. Yu. Degtyareva, et al.
Published: (2019-04-01)

Adverse Drug Reactions and Associated Socio-demographic Factors amongst Drug-resistant Tuberculosis Patients: A Retrospective Review
by: Rajesh Tiwari, et al.
Published: (2025-01-01)

Beyond treatment and cure: Burden of adverse drug reactions in a case of multidrug-resistant tuberculosis
by: Sagarika N. Suresh, et al.
Published: (2025-01-01)

Efficacy and safety data on pretomanid for drug-resistant TB
by: H.T.T. Thuy, et al.
Published: (2025-02-01)

Beta-lactam antibiotics as reserve medications for the treatment of drug-resistant tuberculosis
by: G. N. Mozhokina, et al.
Published: (2021-08-01)

Strategy of the Host-Directed Therapy for Tuberculosis: the Importance of Interferon-Gamma in the Pathogenesis and Therapy of Tuberculosis Infection
by: G. N. Mozhokina, et al.
Published: (2024-03-01)

Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis: A 7-year retrospective cohort study in Addis Ababa, Ethiopia
by: Bisrat Solomon, et al.
Published: (2025-05-01)

Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid
by: V. Chavan, et al.
Published: (2025-02-01)

Adverse events of tuberculosis preventive therapy among individuals with latent tuberculosis infection: A nationwide cohort study in South Korea
by: Sung-Hee Oh, et al.
Published: (2025-07-01)

Prospects for Expanding Drug Therapy for Multiple Drug Resistant and Extensively Drug Resistant Tuberculosis
by: G. N. Mozhokina, et al.
Published: (2022-04-01)